Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROST versus YUVIWEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROST versus YUVIWEL.
LATANOPROST vs YUVIWEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that acts as a selective FP receptor agonist. It increases uveoscleral outflow of aqueous humor by binding to prostanoid FP receptors in the ciliary muscle, leading to matrix metalloproteinase activation and remodeling of the extracellular matrix, thereby reducing intraocular pressure.
YUVIWEL (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces the uptake of monoamines (such as dopamine) into synaptic vesicles, thereby decreasing their release into the synaptic cleft, which reduces dopaminergic transmission implicated in hyperkinetic movement disorders.
Instill one drop (1.5 mcg) of 0.005% ophthalmic solution into the affected eye(s) once daily in the evening.
No established standard dosing for YUVIWEL; drug not recognized.
None Documented
None Documented
Clinical Note
moderateLatanoprost + Unoprostone
"Latanoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateLatanoprost + Hydrochlorothiazide
"Latanoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
Terminal half-life of latanoprost acid is 17 minutes (0.28 hours) systemically; clinically, intraocular pressure reduction persists for 24 hours due to prolonged receptor binding.
Terminal elimination half-life is 12 hours; steady-state reached within 48-60 hours, requiring dose adjustment in renal impairment.
Renal: 88% (metabolites); fecal: 6% (metabolites); unchanged latanoprost is not excreted renally.
Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination constitutes 30%.
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."